Recurrent C. difficile
Recurrent Clostridioides difficile infection (rCDI) is a major healthcare-associated problem: standard-of-care antibiotics (vancomycin, fidaxomicin) themselves disrupt the protective gut microbiota, so 20-30% of patients relapse after a first episode and the risk compounds with each recurrence. Newer microbiota restoration therapies (fecal microbiota transplant, and FDA-approved live biotherapeutics REBYOTA/2022 and VOWST/2023) reduce recurrence but do not directly eliminate the pathogen or its spores. Bacteriophages are attractive here because they are exquisitely strain-specific predators that can lyse C. difficile while sparing the surrounding commensal flora that antibiotics destroy. This species-sparing precision is exactly the property that makes phages a rational complement to, or alternative to, broad-spectrum antibiotics in a recurrence-prone disease driven by microbiome collapse.
How phages act here
Mechanism
C. difficile phages adsorb primarily to the surface-layer protein A (SlpA); the specific S-layer cassette type a strain carries dictates which phages can infect it, which both explains narrow host range and points to how cocktails are rationally assembled to cover multiple ribotypes (Royer et al. 2023; the 2025 PLOS Pathogens structural work maps the SlpA domains required for adsorption to guide broad-host-range engineering). Because no naturally strictly-lytic C. difficile phage has been isolated to date (all characterized phages are temperate and risk lysogeny, which can even upregulate toxin expression in strains like R20291), therapeutic work centers on multi-phage cocktails that suppress resistant/lysogenic escape, and on genetic engineering. The most advanced engineered approach arms a phage to deliver a self-targeting CRISPR array that redirects the bacterium's own endogenous type I-B CRISPR-Cas3 nuclease against its chromosome, killing via two independent routes (irreparable genome degradation plus holin/endolysin lysis) and outperforming wild-type phage in vivo. Phages also penetrate C. difficile biofilms and show synergy/sequencing benefits with antibiotics (e.g., vancomycin pre-treatment improving phage clearance), though spores remain a phage-resistant reservoir, so phages are positioned to target the vegetative, toxin-producing state rather than dormant spores.
Where it stands
Current evidence
As of 2026 there is no completed or registered Phase 2/3 randomized human trial of a phage cocktail for C. difficile; the evidence base is preclinical (in vitro fermenter, Galleria mellonella, and hamster CDI models) plus active commercial preclinical/IND-enabling development. Foundational efficacy comes from Nale/Clokie cocktails (Antimicrob Agents Chemother 2016): three- to four-phage combinations achieved complete lysis in vitro, prevented emergence of resistant/lysogenic clones, reduced colonization by ~4 log in the hamster gut, and extended survival ~33 h, with prophylactic dosing outperforming remedial dosing. The leading engineered program is Locus Biosciences' crPhage (CRISPR-Cas3) platform, built on Selle et al. (mBio 2020), which showed a phage-delivered self-targeting CRISPR reduced C. difficile burden and disease signs in mice; Locus has publicly described C. difficile as a target indication for this platform. The persistent obstacles keeping this out of the clinic are phage temperance/lysogeny (and lysogeny-driven toxin induction), spore resistance, and narrow SlpA-defined host range, all of which current engineering and cocktail-design work is aimed at solving.
Evidence confidence: low
The data
Key studies & trials
- Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, Clokie MRJ. Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo. Antimicrobial Agents and Chemotherapy. 2016;60(2):968-981. ↗
- Selle K, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, Rivera AJ, Montgomery SA, Fortier LC, Barrangou R, Theriot CM, Ousterout DG. In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. mBio. 2020;11(2):e00019-20. ↗
- Royer ALM, Umansky AA, Allen MM, Garneau JR, Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Soutourina O, Fortier LC. Clostridioides difficile S-Layer Protein A (SlpA) Serves as a General Phage Receptor. Microbiology Spectrum. 2023;11(2):e0389422. ↗
- Structural determinants of SlpA-mediated phage recognition in Clostridioides difficile. PLOS Pathogens. 2025;21(1):e1013724. ↗
Who is working on it
Programs & centers
The possibility
If the lysogeny problem is fully solved, the future treatment looks like a precision strike: a CRISPR-armed, lytic-locked phage cocktail tuned to a patient's SlpA-defined strain that wipes out toxigenic C. difficile while leaving the recovering microbiome untouched, potentially given alongside or after a microbiota-restoration therapy to break the recurrence cycle for good. Because phages are self-amplifying and SlpA-targeted, a single well-designed cocktail could be matched to circulating ribotypes much like a vaccine is matched to flu strains, and engineered to deliver genome-destroying payloads rather than merely lysing cells. The realistic near-term niche is as a microbiome-sparing adjunct to antibiotics or FMT, with engineered phages clearing the vegetative pathogen so that restored commensals can outcompete any germinating spores.